Literature DB >> 9811694

Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection.

W Zhang1, S M Lonning, T C McGuire.   

Abstract

Most equine infectious anemia virus (EIAV)-infected horses have acute clinical disease, but they eventually control the disease and become lifelong carriers. Cytotoxic T lymphocytes (CTL) are considered an important immune component in the control of infections with lentiviruses including EIAV, but definitive evidence for CTL in the control of disease in carrier horses is lacking. By using retroviral vector-transduced target cells expressing different Gag proteins and overlapping synthetic peptides of 16 to 25 amino acids, peptides containing at least 12 Gag CTL epitopes recognized by virus-stimulated PBMC from six long-term EIAV-infected horses were identified. All identified peptides were located within Gag matrix (p15) and capsid (p26) proteins, as no killing of target cells expressing p11 and p9 occurred. Each of the six horses had CTL recognizing at least one Gag epitope, while CTL from one horse recognized at least eight different Gag epitopes. None of the identified peptides were recognized by CTL from all six horses. Two nonamer peptide epitopes were defined from Gag p26; one (18a) was likely restricted by class I equine leukocyte alloantigen A5.1 (ELA-A5.1) molecules, and the other (28b-1) was likely restricted by ELA-A9 molecules. Sensitization of equine kidney target cells for CTLm killing required 10 nM peptide 18a and 1 nM 28b-1. The results demonstrated that diverse CTL responses against Gag epitopes were generated in long-term EIAV-infected horses and indicated that ELA-A class I molecules were responsible for the diversity of CTL epitopes recognized. This information indicates that multiple epitopes or whole proteins will be needed to induce CTL in horses with different ELA-A alleles in order to evaluate their role in controlling EIAV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811694      PMCID: PMC110470     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Cytotoxic T-cell recognition of HIV proteins and peptides.

Authors:  D F Nixon; A J McMichael
Journal:  AIDS       Date:  1991-09       Impact factor: 4.177

2.  HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells.

Authors:  R P Johnson; A Trocha; L Yang; G P Mazzara; D L Panicali; T M Buchanan; B D Walker
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

Review 3.  Retroviral vectors as vaccines and immunotherapeutics.

Authors:  D J Jolly; J F Warner
Journal:  Semin Immunol       Date:  1990-09       Impact factor: 11.130

4.  An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag.

Authors:  R A Littaua; M B Oldstone; A Takeda; C Debouck; J T Wong; C U Tuazon; B Moss; F Kievits; F A Ennis
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Induction of anti-HIV-1 immune responses by retroviral vectors.

Authors:  D J Jolly; J F Warner
Journal:  Biotechnol Ther       Date:  1991

6.  Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells.

Authors:  J F Warner; C G Anderson; L Laube; D J Jolly; K Townsend; S Chada; D St Louis
Journal:  AIDS Res Hum Retroviruses       Date:  1991-08       Impact factor: 2.205

7.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection.

Authors:  L E Perryman; K I O'Rourke; T C McGuire
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.

Authors:  C J Issel; D W Horohov; D F Lea; W V Adams; S D Hagius; J M McManus; A C Allison; R C Montelaro
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

10.  Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Authors:  E A Emini; W A Schleif; J H Nunberg; A J Conley; Y Eda; S Tokiyoshi; S D Putney; S Matsushita; K E Cobb; C M Jett
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

View more
  18 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 2.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

4.  Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Authors:  Darrilyn G Fraser; Steve R Leib; Bao Shan Zhang; Robert H Mealey; Wendy C Brown; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

5.  The common equine class I molecule Eqca-1*00101 (ELA-A3.1) is characterized by narrow peptide binding and T cell epitope repertoires.

Authors:  Tobias Bergmann; Carrie Moore; John Sidney; Donald Miller; Rebecca Tallmadge; Rebecca M Harman; Carla Oseroff; Amanda Wriston; Jeffrey Shabanowitz; Donald F Hunt; Nikolaus Osterrieder; Bjoern Peters; Douglas F Antczak; Alessandro Sette
Journal:  Immunogenetics       Date:  2015-09-23       Impact factor: 2.846

6.  Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses.

Authors:  R H Mealey; D G Fraser; J L Oaks; G H Cantor; T C McGuire
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

7.  Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

8.  Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-04-08       Impact factor: 2.046

9.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

10.  Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.

Authors:  R L Tallmadge; M A Brindley; J Salmans; R H Mealey; W Maury; S Carpenter
Journal:  Clin Vaccine Immunol       Date:  2008-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.